Bullish View On Netflix; Akebia Therapeutics Misses Q2 Expectations
- August 25th, 2023
- 515 views
Netflix, Inc. (Nasdaq: NFLX), a prominent streaming entertainment service, was upgraded from Hold to Buy by Loop Capital, accompanied by a revised price target increase from $425 to $500.
With $NFLX closing at $406.93 on Thursday, this updated price target suggests a potential upside of $93.07 or roughly 22.88%, based on the brokerage and advisory firm's analysis.
In other news, Akebia Therapeutics, Inc. (Nasdaq: AKBA), a pharmaceutical company, reported a second-quarter 2023 loss of $(0.06) per share, falling short of the consensus estimate loss of $(0.02). The company's quarterly sales totaled $56.38 million, slightly below analysts' projected revenue of $59.10 million for the period.
$AKBA was trading at $1.21 in pre-market, down $0.04 (-3.19%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
NJCP National Football Conference Names David Dalton Head Coach of Salt Lake Yeti
February 06th, 2026FDA Takes New Approach to "No Artificial Colors" Claims
February 06th, 2026NJCP National Football Conference Announces Micah Deckart as Head Coach of the Idaho Outlaws
February 05th, 2026
Member Login